BioSpace News Archive

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of first patient with a triple combination of ZEN-3694 + Merck’s immune check point inhibitor, KEYTRUDA, + Pfizer’s androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company exercised its option announced on February 2, 2021 and has entered into an exclusive worldwide sub-licensable patent and know-how license agreement

InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that the Company will hold 2021 R&D Day themed on “Science Drives Innovation” in Beijing from 9:00 a.m. to 12:00 p.m. on April 15, 2021.

90% of evaluable patients (27/30) alive and free of major functional disabilities (MFDs) at two years follow-up in Phase 2/3 Starbeam study (ALD-102)

NeoDynamics AB presents an abstract on preclinical results with its novel biopsy system NeoNavia at the St Gallen International Breast Cancer Conference 2021, which is held March 17-21, 2021 in Vienna.

Nyxol Meets Its Primary and Multiple Secondary Endpoints Including Statistically Significant Efficacy Returning Subjects More Rapidly to Normal Pupil Size Across a Breadth of Dilating Agents and Iris Colors

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus announced the acceptance of a late breaking SVV-001 abstract to the American Association for Cancer Research annual meeting.

Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the company will present at one of the Science/AAAS Webinar Series,

- Proceeds to support the acceleration and scaling of ElevateBio’s end-to-end cell and gene therapy technology platform offering - Series C financing led by Matrix Capital Management, joined by additional new investors SoftBank Vision Fund 2 and Fidelity Management & Research Company alongside ElevateBio’s existing investors

LAVA Therapeutics B.V. (“LAVA”, or the “Company”), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that it is expanding its management team with the appointment of Edward F. Smith as its chief financial officer.